Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.
Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70
Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.
Related Posts
Y Combinator Companies To Launch On Wefunder: What This Means To Everyday Investors
Y Combinator announced more than 20 companies from its summer 2022 batch will be launching on Wefunder, a crowdfunding platform connecting startups with investors online.
Binance Shakes Up Workforce Amid Market Woes: Job Cuts Or Strategic Realignment?
In a significant development, Binance (CRYPTO: BNB), the world's largest crypto exchange by trading volume, has confirmed workforce reductions, according to recent reports from both Wu Blockchain and The Block.